The role of the multiple sclerosis (MS) nurse is constantly evolving, owing to the introduction of new MS therapies and new patient treatment 
of a potentially devastating disease. 1 The first, highly successful, MS Nurse Symposium took place in Copenhagen in 2010. The second, larger and more popular MS Nurse Symposium took place in Athens in September 2011 and was attended by over 300 MS nurses from over 30 countries worldwide. This article will provide an overview of the presentations, case study group discussions and attendee feedback on MS nursing issues from the Athens meeting.
General Attendee Feedback
(Chrysa Chrysovitsanou, Athens, Greece)
The care, support and information given by MS nurses are all of critical importance but the role of the MS nurse is changing. Nurses now often work as part of multidisciplinary teams, economic pressures affect care given and the number of different treatments available is increasing. Electronic voting by the attendees showed that most were from university (36.4 %) or community (25.6 %) hospitals.
Fifty-five per cent of nurses stated that the proportion of their patients having MS was >50 % and most nurses were caring for >200 people with MS at any one time (55.4 %). The majority (59.9 %) saw themselves as MS specialists, with 54.4 % reporting that they frequently provided advice and education to people with MS and 74.4 % describing themselves as advisors/intermediaries. The most significant barrier in optimising patient care was regarded as lack of time (30.2 %) and this was followed by a lack of resources, facilities and personnel (29.3 %) . Patients were thought to mostly or always have access to an MS nurse in their country by 83.6 % of nurses.
Key issue responses from attendees collected on a poster showed that a substantial majority (84 %) took a leadership role in the management of people with MS but most (92 %) thought that this should be increased.
The majority of participants (84 %) thought that MS nurse status would be improved with official recognition (see Table 1 ). Ninety-five per cent of attendees believed that a European consensus to define roles would improve nursing practice and that the introduction of oral therapies would significantly change their role in patient care.
Novel Therapies for Multiple SclerosisTheory, Trial and Clinical Practice
Therapeutic Targets -Implications for Clinical Practice (Finn Sellebjerg, Copenhagen, Denmark)
The aetiology of this complex disease is only partially understood.
Various genetic factors have been identified that may contribute to the development of MS, 2 with the risk of acquiring the disease being up to 20-40 fold higher in direct relatives of a person with the disease than in the general population, 3 suggesting that susceptibility is partially genetic, with a polygenic pattern of transmission. In addition to genetic factors, environmental factors such as vitamin D deficiency, smoking, viral infection, temperature/climate and location (latitude) have been associated with higher rates of the disease and are likely risk factors. [4] [5] [6] [7] In MS, there is a balance between central nervous system (CNS)
injury (due to inflammation) and repair and the equilibrium between these two processes determines disease progression. Multiple sclerosis involves an autoimmune process in which T-cell lymphocytes recognise myelin as foreign and attack it, leading to damage, inflammation and neurodegeneration. The critical role of T cells in MS has led to these cells and associated factors providing key targets for disease-modifying therapies (DMTs). The main objective when treating MS is halting the immune attack on myelin and this can be achieved through either a general reduction of the immune response (e.g. mitoxantrone) or using a selective approach to inhibit a single effect (e.g. interferon betas [IFNβs] , natalizumab or
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Figure 1: Novel Treatments and Their Targets in Multiple Sclerosis
Development discontinued/withdrawn In development Approved
Fingolimod
Reversibly blocks lymphocytes from leaving the lymph nodes and subsequently entering the central nervous system (CNS)
Teriflunomide
Reversible, non-competitive inhibitor of an enzyme essential for pyrimidine synthesis. Inhibits expansion of B and T-cells and antibody production
Laquinimod

Immunomodulatory effect. Inhibits infiltration of inflammatory cells, CD4 + T-cells and macrophages into CNS. Suppresses antigen presentation
BG-12
Several possible targets: Nrf2 antioxidant pathway; immunosupression; NFkB pathway, decreasing cytokine release and T-cell apoptosis; inhibition of adhesion molecules
Alemtuzumab
Monoclonal antibody to CD52, depletion of B-cells, T-cells and monocytes
Cladribine
Purine nucleoside analogue which produces selective lymphocyte depletion through inhibition of DNA synthesis and repair. Decreases pro-inflammatory cytokines fingolimod). However, it is also important that this effect on the immune system is reversible. Novel oral agents currently available or in late-stage development for the treatment of MS are shown in Figure 1 and although all have been shown to act on lymphocytes, they do so in a variety of different ways. Fingolimod, for example modulates S1P receptors, reducing inflammation. Teriflunomide reversibly blocks DNA synthesis; laquinimod suppresses antigen presentation although its molecular target is unknown; BG-12 has several possible modes of action on cytokines and apoptosis; and alemtuzumab is a CD52-specific monoclonal antibody leading to depletion of B cells, T cells and monocytes.
Assessing the Clinical Evidence (Martin Duddy, Newcastle upon Tyne, UK)
In MS treatment there are three overall goals -preventing/shortening relapses, preventing or delaying disability accumulation and addressing existing disabilities. As mentioned above, there are several potential oral therapies (see Figure 2 ) in different stages of development for the treatment of MS and three of these drugs are currently undergoing Phase III trials. Teriflunomide, a DNA synthesis inhibitor, is currently undergoing trials versus placebo, versus IFNβ and is also being assessed for use in clinically isolated syndrome (CIS).
In the Phase III TEMSO trial, teriflunomide reduced annualised relapse rate (ARR) in MS by 31 % versus placebo. 9 Laquinimod, an oral 13 and TRANSFORMS (versus IFNβ) studies 14 support its use in RRMS. In the FREEDOMS trial, 13 ARR was reduced by 54 % (p<0.001), time to disability progression confirmed after six months was reduced by 37 % and
Gd-enhancing lesions were reduced by 82 % compared with placebo at two years. In the TRANSFORMS trial, ARR was reduced by 52 % have received misinformation and need to be corrected (see Table 2 ).
Alternatively, some patients (13.6 %) are poorly informed and need good quality guidance on the management of their condition. Certain parameters such as ARR, risk of disability progression, MRI changes and adverse side effects, can be challenging to explain to people with MS (see Table 2 ). After treatment has been decided, there are a variety of factors that can affect patient adherence and these include:
economics; healthcare organisation issues (such as access to MS nurses); condition-related factors; patient-related factors (injection fear, etc.); and therapy-related factors. Multiple sclerosis nurses need to listen, communicate, keep their knowledge current, understand, explore treatments, decide on best strategies and monitor patient progress.
What's New in Established Interventions?
Evidence for Established Therapies (Tjalf Ziemssen, Dresden, Germany)
Although various potential new treatments are in development for the treatment of MS (see Figure 2 ), the IFNβs and glatiramer acetate (GA)
continue to be the mainstay of MS treatment. The audience vote showed the people with MS cared for by the attendees most commonly receive IFNβ-1a three times weekly (TIW), IFNβ-1a weekly or IFNβ-1b every other day (see Table 2 ). In CIS, patients most commonly receive IFNβ-1a TIW but a sizeable proportion (21.8 %) of attendees said their patients receive no treatment at all at this stage.
It is important to stress the rationale for starting disease modifying treatment early, as illustrated by the BENEFIT trial in which there was a 42.4 versus 53.4 % conversion to clinically definite MS for patients receiving early versus delayed treatment. 16 When treating RRMS, the traditional first-line therapies (IFNβs and GA) provide similar efficacy Natalizumab is a highly effective DMT for use in highly active RRMS, and has been demonstrated to reduce the relapse rate from 0.78/year to 0.26/year in one study. 19 A major safety issue with this therapy months. 20 Mitoxantrone can be used in the late stages of MS but is approved for use in MS in only a limited number of countries and is used much less now owing to safety issues. There is no standard treatment for MS as it is an individual disease that varies according to the patient. 21 As treatment options increase, treatment decisions will get more and more complex, although the concept of individualised therapies in MS remains a pipe dream. Due to the complex nature of MS, multidisciplinary teams are needed to implement appropriate treatment plans.
Autoinjector Update (Mathias Bruns, Berlin, Germany)
Both IFNβ and GA therapy require parenteral self-administration by either subcutaneous or intramuscular injection and, because of this, patient compliance can be an issue. In addition, adverse effects can occur and in patients undergoing IFNβ and GA therapy, injection site reactions (ISRs) were considered by the participants to be as challenging as flu-like symptoms (see Table 2 ). To increase patient compliance, the patient experience must be improved and there are several ways in which this can be achieved. First, it has been demonstrated that using smaller (narrower) needles and autoinjectors improves patient experiences and improves adherence. [22] [23] [24] Second, rotation of the injection site can reduce ISRs, pain and trauma and may improve compliance. 25 In addition, autoinjectors can be helpful for patients with limited mobility or dexterity and provide the ability to administer injections at body sites that were previously inaccessible. The key aspects influencing a nurse's ability to provide support to people with MS are increasing patient numbers, access to new technology and changes in patient-practitioner relationships (see Table 2 ). In Canada there are an estimated 75,000 people with MS, which is an increase on previous estimations but prevalence has been shown to vary between regions of the country. 
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The Evolving Role of the Multiple Sclerosis Nurse -Implications of Future Management Directions fully -now has mobility problems after two months of treatment • What is the role of work in individuals with SPMS?
• MS nurses need to improve their skills to manage patients with SPMS;
should be part of a network and should be able to deal with problems, e.g., incontinence
• Multiple Sclerosis Table 4 .
Summary of Conference Posters
A series of studies, conducted by participating nurse groups from various clinical centres, were presented as posters, mostly focusing on the substantial improvements that could be gained from greater communication with patients and providing enhanced support leading to better treatment adherence (see Table 5 ). The MS-NEED study was a large-scale telephone survey of 280 nurses from the Czech Republic, Finland, Germany, Italy, Poland and the UK that determined
Multiple Sclerosis the wide range of roles and responsibilities adopted by MS nurses and their importance in patient management (see Figures 3 and 4) .
Although this study highlighted the leading role that MS nurses take in patient management, some respondents felt that standards of care in MS are not well maintained at all treatment centres and that marked differences in practice exist between the countries included.
The study also indicated the need for a consensus framework to define roles and responsibilities, to establish best practice and to ensure improved outcomes in MS across Europe.
Conclusions
As novel MS therapies are introduced and new patient treatment strategies emerge, the role of the MS nurse is constantly evolving. They must be knowledgeable about advances in MS treatments and have 
